Bendamustine and cetuximab as an alternative therapeutic option for recurrent head and neck squamous cell carcinoma.

Tschechne, B.; Wildfang, I.; Niebuhr, H.; Borghardt, J.; Zakaria, Hesham Mostafa; Fanaei, S.; Luft, S; Jordan, Weston

doi:10.1200/jco.2010.28.15_suppl.e16029

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, the study generated 25 grade 4 adverse events and three grade 4 events [ 66 ]. Finally, a recent abstract found the combination of bendamustine and cetuximab in relapsed squamous cell carcinoma of the head and neck resulted in partial response rate of 36% and stable disease in 36% of patients ( n = 28) who had failed prior therapy [ 67 ].…”

Section: Cetuximab: Palliative Treatmentmentioning

confidence: 99%

The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck

Russell

Colevas

2012

Chemotherapy Research and Practice

View full text Add to dashboard Cite

Targeting of the EGF receptor (EGFR) has become a standard of care in several tumor types. In squamous cell carcinoma of the head and neck, monoclonal antibodies directed against EGFR have become a regular component of therapy for curative as well as palliative treatment strategies. These agents have anti-tumor efficacy as a single modality and have demonstrated synergistic tumor killing when combined with radiation and/or chemotherapy. While cetuximab has been the primary anti-EGFR monoclonal antibody used in the US, variant anti-EGFR monoclonal antibodies have been used in several clinical studies and shown benefit with improved toxicity profiles. Next generation anti-EGFR monoclonal antibodies may demonstrate multi-target epitope recognition, enhanced immune cell stimulation, or conjugation with radioisotopes in order to improve clinical outcomes. Identification of the specific patient subset that would optimally benefit from anti-EGFR monoclonal antibodies remains an elusive goal.

show abstract

Section: Cetuximab: Palliative Treatmentmentioning

confidence: 99%